SAb Biotherapeutics

S Ab Biotherapeutics

Pharmaceuticals, 2100 E 54th St N, Sioux Falls, South Dakota, 57104, United States, 51-200 Employees

sab.bio

  • twitter
  • LinkedIn

phone no Phone Number: 60********

Who is SAB BIOTHERAPEUTICS

A clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of...

Read More

map
  • 2100 E 54th St N, Sioux Falls, South Dakota, 57104, United States Headquarters: 2100 E 54th St N, Sioux Falls, South Dakota, 57104, United States
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $50 Million to $100 Million

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2836

checked-icon Does something look wrong? Fix it. | View contact records from SAB BIOTHERAPEUTICS

SAb Biotherapeutics Org Chart and Mapping

Employees

Dean Crichton

Research Associate Dmd

Kelsey Schriever

Senior Research Associate

Peter Boerema

Director of Animal Regulatory Affairs

Ema Althoff

Senior Research Associate II

Russell Beyer

Chief Financial Officer

Melissa Ullerich

Chief Corporate Communications & Investor Relations Officer

Ellen Lewis

Research Associate of Antigen Production

Sivakumar Nadarajah

Executive Director, Quality Control

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding SAb Biotherapeutics

Answer: SAb Biotherapeutics's headquarters are located at 2100 E 54th St N, Sioux Falls, South Dakota, 57104, United States

Answer: SAb Biotherapeutics's phone number is 60********

Answer: SAb Biotherapeutics's official website is https://sab.bio

Answer: SAb Biotherapeutics's revenue is $50 Million to $100 Million

Answer: SAb Biotherapeutics's SIC: 2836

Answer: SAb Biotherapeutics has 51-200 employees

Answer: SAb Biotherapeutics is in Pharmaceuticals

Answer: SAb Biotherapeutics contact info: Phone number: 60******** Website: https://sab.bio

Answer: A clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D)

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access